Tokyo Tape
Sign in
← Alfresa Holdings

Quarterly report · Q2

2784.TEDINET S100PL0M
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥1.33T2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥2.59T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥1.29T2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥10.2bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥9.1bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥11.5bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥32.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥11.0bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥11.1bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥10.3bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥7.0bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥32.2bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥7.0bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥7.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥7.0bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥1.33Tat 2022-09-30Cons.Assets
Total assets¥1.30Tat 2022-03-31Cons.Assets
Total assets¥1.33Tat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥852.3bnat 2022-09-30Cons.Liabilities
Total liabilities¥832.2bnat 2022-03-31Cons.Liabilities
Net assets / equity¥481.9bnat 2022-09-30Cons.Net assets
Net assets / equity¥471.8bnat 2022-03-31Cons.Net assets
Net assets / equity¥492.0bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥169.5bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥180.4bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥168.2bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥179.1bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥176.0bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥169.1bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥10.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥36.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥20.9bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥15.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥2.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥29.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥6.9bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥34.62022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥24.12022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥153.572021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥33.022021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥17.72021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio36.1%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio36.2%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio36.9%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥15.2bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥15.2bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥245m
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.18T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.17T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥8.3bn
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥23.6bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥17.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥6.6bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥842m
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥17.9bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥17.9bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥14m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥124.1bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥123.8bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥305m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥1.35T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥1.33T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥15.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥10.0bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥14.2bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥14.2bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30¥182m
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥1.13T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥1.13T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥7.9bn
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥7.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥22.9bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥16.9bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥6.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.1bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥16.8bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥16.8bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentsegment profit2021-04-01 → 2021-09-30−¥285m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥129.9bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥129.6bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥284m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥1.30T
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥1.29T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥14.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥8.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 539
ItemContextValueUnit
Selling general and administrative expensesCurrentYTDDuration80812000000JPY
Operating incomePrior1YTDDuration9117000000JPY
Operating incomeCurrentYTDDuration10227000000JPY
Interest income noiPrior1YTDDuration33000000JPY
Interest income noiCurrentYTDDuration30000000JPY
Dividends income noiPrior1YTDDuration1220000000JPY
Dividends income noiCurrentYTDDuration825000000JPY
Real estate rent noiPrior1YTDDuration305000000JPY
Real estate rent noiCurrentYTDDuration297000000JPY
Other noiPrior1YTDDuration494000000JPY
Other noiCurrentYTDDuration330000000JPY
Non operating incomePrior1YTDDuration2054000000JPY
Non operating incomeCurrentYTDDuration1483000000JPY
Interest expenses noePrior1YTDDuration39000000JPY
Interest expenses noeCurrentYTDDuration34000000JPY
Rent expenses on real estates noePrior1YTDDuration94000000JPY
Rent expenses on real estates noeCurrentYTDDuration93000000JPY
Other noePrior1YTDDuration81000000JPY
Other noeCurrentYTDDuration95000000JPY
Non operating expensesPrior1YTDDuration215000000JPY
Non operating expensesCurrentYTDDuration222000000JPY
Ordinary incomePrior1YTDDuration10956000000JPY
Ordinary incomeCurrentYTDDuration11488000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration46000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration104000000JPY
Gain on sales of investment securities eiPrior1YTDDuration153000000JPY
Gain on sales of investment securities eiCurrentYTDDuration237000000JPY
Extraordinary incomePrior1YTDDuration199000000JPY
Extraordinary incomeCurrentYTDDuration341000000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration0JPY
Loss on sales of noncurrent assets elCurrentYTDDuration15000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration83000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration37000000JPY
Impairment loss elPrior1YTDDuration16000000JPY
Impairment loss elCurrentYTDDuration1000000JPY
Loss on valuation of investment securities elPrior1YTDDuration664000000JPY
Loss on valuation of investment securities elCurrentYTDDuration695000000JPY
Other elPrior1YTDDuration77000000JPY
Other elCurrentYTDDuration5000000JPY
Extraordinary lossPrior1YTDDuration842000000JPY
Extraordinary lossCurrentYTDDuration755000000JPY
Income before income taxesPrior1YTDDuration10313000000JPY
Income before income taxesCurrentYTDDuration11074000000JPY
Income taxes currentPrior1YTDDuration6833000000JPY
Income taxes currentCurrentYTDDuration8035000000JPY
Income taxes deferredPrior1YTDDuration-3506000000JPY
Income taxes deferredCurrentYTDDuration-4005000000JPY
Income taxesPrior1YTDDuration3326000000JPY
Income taxesCurrentYTDDuration4029000000JPY
Profit lossPrior1YTDDuration6986000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass